Tocilizumab - Chugai Pharmaceutical/Roche
Alternative Names: Actemra; ACTPen; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemraLatest Information Update: 07 May 2024
At a glance
- Originator Chugai Pharmaceutical; Osaka University
- Developer Assistance Publique Hopitaux de Paris; Biomedical Advanced Research and Development Authority; Charite - Universitatsmedizin Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University Hospital Tubingen; University of Bern; University of Pittsburgh
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections; COVID-19 pneumonia; Drug hypersensitivity; Giant cell arteritis; Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis; Systemic scleroderma
- Registered Adult-onset Still's disease; Vasculitis
- Phase III Osteoarthritis
- Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Familial Mediterranean fever; Polymyalgia rheumatica; Polymyositis; Pulmonary arterial hypertension; Schnitzler syndrome
- Phase I/II Urogenital cancer
- Phase I Pancreatic cancer
- No development reported Chronic lymphocytic leukaemia
- Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Systemic lupus erythematosus
Most Recent Events
- 27 Mar 2024 Roche completes phase-I clinical trials in COVID-2019 infections (Adjunctive treatment, In infants, In children, In adolescents, In neonates) in US, Brazil, Croatia, France, Germany, Spain, Italy , Poland, South Africa, UK and Greece (IV) (NCT05164133)
- 13 Sep 2023 Regulatory submission withdrawn for Systemic scleroderma in European Union (SC)
- 09 May 2023 Registered for COVID-19 pneumonia in Taiwan (IV) before May 2023 (Chugai Pharmaceuticals pipeline, May 2023)